Genotype for Precision Psychiatry
Researchers at Mount Sinai utilized a large biobank to implement a recall-by-genotype framework for precision psychiatry. The study successfully recontacted participants with rare genetic variants linked to neurodevelopmental disorders, demonstrating the value of combining genomic data with clinical assessments.
Why it matters
This framework provides a scalable method for identifying genetic risk factors for complex psychiatric conditions, potentially accelerating personalized treatment development.
Summary: A new study provides a practical framework for recall-by-genotype (RbG) research within large, diverse healthcare system biobanks to advance precision psychiatry.
Researchers utilized Mount Sinai’s BioMe biobank to identify and recontact individuals carrying rare copy number variants (CNVs) linked to high risks of neurodevelopmental disorders, including autism spectrum disorder, intellectual disability, and schizophrenia.
The team successfully recontacted 892 participants across diverse ancestral backgrounds, demonstrating that direct clinical and cognitive phenotyping captures critical diagnostic nuances beyond standard electronic health records (EHRs).
Clinical biobanks that combine genomic data with electronic health records (EHRs) have become powerful resources for discovering genetic variants associated with disease. These biobanks may also be used to identify individuals carrying clinically relevant genetic variants for participation in clinical research focusing on brain health.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in